NCT07360964进行中（未招募）不适用
Clear Cell Chondrosarcoma in Italy: Insights Into Radiological, Clinical and pathologicaL Features, With Emphasis on Prognosis (CIRCLE)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 77
研究概览
简要总结
Clear cell chondrosarcoma of bone is considered a low-grade malignant tumor in the last WHO classification of soft tissue and bone tumors; however, it is reported that recurrences and metastasis can occur. Considering the uncertain prognosis of this rare tumor, with some cases that historically seems to pursue a bad prognosis, we decided to collect all the Italian cases of clear cell condrosarcoma, in order to better understand its natural history and prognosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients with diagnosis of clear cell chondrosarcoma and chondrosarcoma with a clear cell component treated from 01 Jan 1982 to 31 Dec 2023
- •Information available (date of primary tumor diagnosis, local treatments, systemic treatment, response to systemic treatment, date of progression) and date and status at last follow-up
- •Imaging studies available for revision
- •Histological slides available for revision
排除标准
- •- Diagnosis different from clear cell chondrosarcoma or chondrosarcoma with a clear cell component;
- •Absence of radiological and/or clinical data
研究者
相似试验
尚未招募
不适用
Evaluation of Tumor Resection and Reconstruction With Prosthetic ImplantsBone TumorNCT07337018Fondazione Policlinico Universitario Agostino Gemelli IRCCS100
招募中
不适用
Diagnostic and Therapeutic Targets in Cartilaginous TumoursNCT07315542St. Anne's University Hospital Brno, Czech Republic300
招募中
2 期
To evaluate the efficacy and safety of regorafenib in patients with refractory primary bone tumors.2024-514720-17-00Instytut Matki I Dziecka30
招募中
2 期
Kidney cancer2023-505605-16-00Oncorena AB, Oncorena AB65
尚未招募
2 期
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune IntoleranceNCT07313202Fujian Cancer Hospital72